Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.71 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407973 | 0.83 | DPP4 (1.00) | DPP4DPP8 | |
| SCHEMBL4482924 | 0.82 | DPP4 (0.82) | DPP4DPP8CNR1THRB | |
| SCHEMBL1408245 | 0.81 | DPP4 (0.75) | DPP4DPP8CNR1THRBKDM4E | |
| SCHEMBL1408244 | 0.79 | DPP4 (0.67) | DPP4DPP8CNR1THRBTP53 | |
| SCHEMBL12809639 | 0.75 | DPP4 (0.85) | DPP4DPP8 | |
| SCHEMBL4501648 | 0.72 | DPP4 (0.48) | DPP4DPP8 | |
| SCHEMBL4486566 | 0.71 | DPP4 (0.55) | DPP4DPP8 | |
| SCHEMBL5241745 | 0.70 | DPP4 (0.47) | DPP4DPP8 | |
| SCHEMBL4486078 | 0.70 | DPP4 (0.55) | DPP4DPP8 | |
| SCHEMBL4494980 | 0.70 | DPP4 (0.57) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 4/4885CNR1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.